SCHEMBL1899392

SCHEMBL1899392

Nc1cc(-c2ccccc2)cc(OCc2ccccc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 1/20 0.51
▸ MPO P05164 1/20 0.46
▸ HRH4 Q9H3N8 1/20 0.45
▸ GABRG2 P18507 2/20 0.45
▸ GABRB3 P28472 2/20 0.45
▸ GABRA5 P31644 2/20 0.45
▸ GABRA3 P34903 2/20 0.45
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAOB P27338 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAOA P21397 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ LTA4H P09960 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ AGXT P21549 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13884791 0.83 NUDT1 (0.57) NUDT1MPOHRH4MAOBMAPT
SCHEMBL1901119 0.81 GRM5 (0.48) NUDT1HRH4GABRG2GABRB3GABRA5
SCHEMBL6266136 0.80 NUDT1 (0.66) NUDT1MPOHRH4MAOBMAPT
SCHEMBL2144937 0.76 NUDT1 (0.49) NUDT1MPOHRH4MAOBMAPT
SCHEMBL25350701 0.75 MAPK1 (0.53) NUDT1MEN1KMT2AMAOBMAPT
Bromide SCHEMBL5755353 0.75 NUDT1 (0.48) NUDT1MPOHRH4MAOBMAPT
SCHEMBL17611047 0.75 GABRA5 (0.51) NUDT1GABRG2GABRB3GABRA5GABRA3
SCHEMBL901375 0.74 MEN1 (0.60) MEN1KMT2AMAPTRAB9AMAOA
SCHEMBL15305717 0.74 MAOB (0.58) MPOMEN1KMT2AMAOBMAPT
SCHEMBL2037015 0.73 NUDT1 (0.47) NUDT1MPOHRH4GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 — — US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 — — US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 — — EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 NUDT1 2959/4885MPO 4826/4885HRH4 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback